HYMOVIS® (German)

HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics.

HYMOVIS is indicated for the treatment of pain in osteoarthritic joints and in the conservative treatment of the meniscal lesion of the knee and for the improvement of joint mobility through the enhancement of synovial fluid viscoelasticity.

Hymovis® is a viscoelastic hydrogel contained in a single-use syringe, based on ultra-pure hyaluronan. It exhibits greater viscosity, elasticity, and joint residence time, leading to increased joint lubrication with reduced friction. Hymovis® has the ability to withstand repeated mechanical stress and has a prolonged residence time in articular joints, which contributes to its efficacy. It is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have not responded adequately to conservative non-invasive therapy. Furthermore, Hymovis® has been shown to slow down cartilage damage and improve lubrication and shock-absorbing properties in joints.

• Strict aseptic injection technique should be employed during the administration of HYMOVIS®.
• The pre-filled syringes are intended for single use only.
• The contents of the syringe are sterilized by moist steam and should be used immediately after opening.
• Discard any unused HYMOVIS®.
• Do not re-sterilize.
• Do not use HYMOVIS® if the package has been opened or damaged.
• HYMOVIS® should be stored in its original package at room temperature (below 77°F/25°C). DO NOT FREEZE.
• It is recommended to remove joint effusion, if present, before injecting HYMOVIS®.
• Only properly licensed medical professionals trained in accepted injection techniques for delivering agents into the knee joint should inject HYMOVIS® for the indicated use.

Contraindications

• Do not administer to patients with known hypersensitivity (allergy) to hyaluronate preparations.
• Do not administer to patients with known hypersensitivity (allergy) to gram-positive bacterial proteins.
• Do not administer to patients with infections or skin diseases in the area of the injection site or joint.

After-care

• Transient pain or swelling may occur after the intra-articular injection.
• It is recommended that patients avoid strenuous or prolonged (i.e., more than one hour) physical activities within 48 hours following the intraarticular injection.